Furthermore, combination therapies that pair GM-CSF with small molecule inhibitors of apoE or CSF1R at appropriate neuroinflammatory stages may be particularly effective for treating people with DS and/or AD. The gene discussed is CSF2; the disease is Dravet syndrome.